Ganetespib

Generic Name: Ganetespib

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀N_₄O_₃

CAS Number: 888216-25-9

Unique Ingredient Identifier: 2E8412Y946

Background: Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.

Clinical Trials

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Ovarian Cancer

Interventions: Drug: Ganetespib
Drug: Niraparib
Drug: Carboplatin
Drug: Paclitaxel
Drug: Gemcitabine

First Posted Date: 2018-12-21

Last Posted Date: 2023-09-15

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 122

Registration Number: NCT03783949

Locations: 🇮🇹
Azienda Ospedaliero Bologna, Bologna, Italy
🇩🇪
Universitätsklinikum Dresden, Dresden, Germany
🇦🇹
Medical University of Innsbruck, Innsbruck, Austria

and more 10 locations

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Not Applicable

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Ganetespib
Drug: Paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2015-12-22

Last Posted Date: 2016-05-30

Lead Sponsor: University of Chicago

Registration Number: NCT02637375

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

Phase 1

Completed

Conditions: Stage IIB Esophageal Cancer AJCC v7
Stage IIIA Esophageal Cancer AJCC v7
Malignant Neoplasm of the Cervical Esophagus
Malignant Neoplasm of the Thoracic Esophagus
Stage IIA Esophageal Cancer AJCC v7
Stage IIIC Esophageal Cancer AJCC v7
Gastroesophageal Junction Adenocarcinoma
Stage IIIB Esophageal Cancer AJCC v7

Interventions: Drug: Carboplatin
Drug: Ganetespib
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2015-03-17

Last Posted Date: 2019-07-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT02389751

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Phase 1

Terminated

Conditions: Stage III Oropharyngeal Squamous Cell Carcinoma
Stage IVA Laryngeal Squamous Cell Carcinoma
Stage II Hypopharyngeal Squamous Cell Carcinoma
Stage II Oropharyngeal Squamous Cell Carcinoma
Stage I Laryngeal Squamous Cell Carcinoma
Stage II Laryngeal Squamous Cell Carcinoma
Stage III Hypopharyngeal Squamous Cell Carcinoma
Stage III Laryngeal Squamous Cell Carcinoma
Stage IVA Hypopharyngeal Squamous Cell Carcinoma
Stage IVA Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: Ganetespib
Procedure: Therapeutic Conventional Surgery
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-01-08

Last Posted Date: 2016-07-26

Lead Sponsor: Emory University

Target Recruit Count: 3

Registration Number: NCT02334319

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Phase 1

Terminated

Conditions: Cancer
Small Cell Lung Cancer

Interventions: Drug: Ganetespib
Drug: Doxorubicin

First Posted Date: 2014-10-10

Last Posted Date: 2018-04-23

Lead Sponsor: Georgetown University

Target Recruit Count: 11

Registration Number: NCT02261805

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: Ziv-Aflibercept
Drug: Ganetespib

First Posted Date: 2014-07-17

Last Posted Date: 2018-03-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT02192541

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Phase 1

Completed

Conditions: Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
HER2-positive Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IIIA Breast Cancer

Interventions: Drug: ganetespib
Drug: paclitaxel
Biological: trastuzumab
Biological: pertuzumab

First Posted Date: 2014-02-12

Last Posted Date: 2018-06-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT02060253

Locations: 🇺🇸
NYU Cancer Institute, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Phase 1

Terminated

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Ganetespib
Drug: Paclitaxel

First Posted Date: 2013-12-16

Last Posted Date: 2019-08-13

Lead Sponsor: Medical University Innsbruck

Target Recruit Count: 133

Registration Number: NCT02012192

Locations: 🇧🇪
Katholieke Universiteit Leuven, Dept. of Gynaecologic Oncology, Leuven, Belgium
🇩🇪
Universitätsklinikum Hamburg-Eppendorf Dept. of Gynecology and Gynecologic Oncology, Hamburg, Germany
🇩🇪
University Hospital Carl Gustav Carus Dresden, Department of Gynaecology and Obstetrics, Dresden, Germany

and more 7 locations

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Phase 1

Completed

Conditions: Malignant Peripheral Nerve Sheath Tumors (MPNST)
Sarcoma

Interventions: Drug: ganetespib
Drug: Sirolimus

First Posted Date: 2013-12-11

Last Posted Date: 2019-05-15

Lead Sponsor: Sarcoma Alliance for Research through Collaboration

Target Recruit Count: 20

Registration Number: NCT02008877

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 4 locations

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Terminated

Conditions: Recurrent Primary Peritoneal Cavity Cancer
Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: ganetespib
Other: laboratory biomarker analysis

First Posted Date: 2013-10-16

Last Posted Date: 2024-03-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 12

Registration Number: NCT01962948

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy